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Objective: A descriptive study of drug-resistance patterns by age group and among culture-
positive pulmonary tuberculosis (TB) patients referred to the Research Institute for Pul-
monology and Phthisiology of Belarus between January 2007 and January 2008.
Methods: Drug susceptibility tests were performed for first- and second-line anti-tuberculo-
sis drugs. Patients were clustered into five resistance categories: mono-resistant (Mono);
multi-drug resistant (MDR); all first-line drug resistance (MDR + ES); and extensively drug
resistant (XDR). The patients were divided into primary and secondary and into six groups
based on age in years (<15, 15–24, 25–44, 45–54, 55–65, and >65).
Results: An analysis was undertaken of information gathered from 934 TB patients, of
whom 660 were men (70.67 ± 1.5%) and 274 were women (29.33 ± 1.5%) (p < 0.001). In the
age group 25–65 years, men outnumbered women between 2.7 and 9.0 times higher. Cases
of secondary TB totaled 414 (52.02 ± 1.77%), and primary cases totaled 382 (47.98 ± 1.77%)
(p > 0.05); 756 of the patients were of working age, and 170 were of non-working age, of
whom 570 men of working age (18–60 years) and 188 women of working age (18–55 years)
participated. Males were significantly more likely to have MDR-TB than females. All cases
with XDR-TB were older than 14 years old.
Conclusion: As Belarus is a high-burden MDR-TB country and treatment of drug-resistant
TB is long and complicated, the findings of this study provided useful information to deliver
effective community-based disease control measures and a proposed plane for the effec-
tive management of drug-resistant TB at the national level.
 2012 Asian-African Society for Mycobacteriology. All rights reserved.Introduction person is newly infected with MTB. There are more thanTuberculosis (TB) causes huge consequences in different
societies. One out of every three individuals is infected with
Mycobacterium tuberculosis (MTB), which means around
2 billion people total. Further, every second of every day a-African Society for Myco
losis and Pediatric Infect
ences, Arak, Iran.
om, arjomandzadegan@a8 million new cases and 1.7 million deaths annually [1].
TB (all forms) accounts for 2.5% of the global burden of
disease and is the most common cause of death in young
women, killing more women than all causes of maternal mor-
tality combined [1,2]; 75% of people with TB are within thebacteriology. All rights reserved.
ious Disease Research Center, Departments of Microbiology and
rakmu.ac.ir (M. Arjomandzadegan).
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in Europe, 445,000 people become sick with TB and 8 people
die because of TB every day; 75% of these deaths occur in
Eastern Europe. Among the cases of those who registered
for treatment and reported to the World Health Organization
(WHO) in 2005, the ratio of men to women was 1:0.7.
Belarus is one of the 18 prior countries for TB control in the
WHO European Region [4,5] and one of the 25 preceding mul-
ti-drug resistant-TB (MDR-TB) and extensively drug resistant-
TB (XDR-TB) countries [5]. In 2007, the estimated total number
of MDR-TB cases in Belarus was 707, and 579 MDR-TB patients
were receiving treatment (including XDR). At the same time,
68 XDR-TB patients were under treatment [6].
Alternatives such as exposure, risk of infection, and pro-
gression from infection to disease are some epidemiological
differences which will describe the reason for the higher rate
of TB incidence in men. However, some researches reveal that
women in their early reproductive ages may have higher rates
of progression from infection to disease and case fatality as
well [7].
In San Francisco, the male to female ratio was 2:1 (95% CI
1.9–2.3) in the year 2000. Analyses revealed differences in sex-
specific rates after the age of 14 and the highest male/female
ratios were seen in the American populations [8].
In almost all countries below the poverty line, twice as
many men than women are reported with TB. Biological
mechanisms might be one of the causes of this difference;
however, socio-economic and cultural issues also influence
the availability of health care, which leads to underreporting
in females. Thus, gender needs to be considered as an effec-
tive factor in TB control programs [9].
Prevalent data and reporting from 29 surveys in 14 coun-
tries were used by Borgdorff [10]. Notification rates fluctuate
dramatically in different countries, but the male/female ratio
remains below 1 and declines owing to increasing age nearly
in all countries. The female/male (F/M) prevalence ratio was
less than 0.5 in surveys in South-East Asia and the Western
Pacific Region, andwas approximately 1 in the African Region.
MDR-TB is TB that is resistant to at least two of the best
anti-TB drugs—Isoniazid (INH) and Rifampicin (RIF). These
two drugs are known as first-line drugs and are prescribed
in all TB patients’ treatments [2,5]. MDR-TB has become a very
serious problem in most countries of the Commonwealth of
Independent States (CIS), more serious than in any other
places in the world. This is mainly because present treat-
ments are inappropriate, drug shortages occur intermittently
and patients receiving treatments are being poorly monitored
as well [11]. TB patients in parts of Eastern Europe and Central
Asia are 10 times more likely to have MDR-TB than those in
the rest of the world [12].
Another type of drug-resistant TB is called extensively drug
resistant TB (XDR-TB), which is relatively rare. XDR-TB is de-
fined as TB that is resistant to INH andRIF, along with resis-
tance to any fluoroquinolone and at least one of three
injectable second-line drugs (i.e., Amikacin, Kanamycin, or
Capreomycin). XDR-TB is resistant to both first- and second-
line drugs; therefore, patients suffering from this kind of TB
havenoother choices except themuch less effective treatment
options. Individualswith HIV infection or any other conditions
whichmay render the immune systemweaker aremore threa-tened by XDR-TB. These individuals are more likely to develop
TB once they are infected, and they also have a higher risk of
death once they develop TB [13]. According to reports from
the WHO during 2000–2004, 20% and 2% of 17,690 TB isolates
in the world were MDR and XDR, respectively [14].
The aim of this study was to determine high risk groups
for MDR-TB and XDR-TB within different age and sex groups
those TB patients in Belarus in a population study that in-
cluded all cases of active culture-positive TB that have been
referred to the National Reference Laboratory of the Research
Institute for Pulmonology and Phthisiology from January 2007
to January 2008.Material and methods
Study population and methods
The 934 culture-positive sputum samples referred to the Na-
tional Reference Laboratory of the Research Institute for Pul-
monology and Phthisiology in Minsk from January 2007 to
January 2008 were analyzed; 40% of these samples were ob-
tained from Minsk’s patients (hospitalized in Minsk) and
60% from other regions (hospitalized in Minsk and other re-
gions)—equal to patient’s population in the regions.
Drug susceptibility testing
All 934 cases were subjected to a drug-resistance test. The
anti-microbial drug susceptibility tests (DST) were performed
using the WHO standard conventional proportional method.
The Preferable First Line Drugs were INH 1 mcg/ml, RIF
40 mcg/ml, Ethambutol (EMB) 2 mcg/ml, and Streptomycin
(SM) 10 mcg/ml on slants with the H37Rv strain of MTB as
the positive control. Furthermore, MDR isolates were tested
for resistance to fluoroquinolones and three injectable drugs
(Amikacin 8 mcg/ml, Kanamycin 30 mcg/ml, and Capreomy-
cin 8 mcg/ml) for detection of XDR isolates.Definitions
First- and second-line drugs are the two main categories of
drugs used for TB treatment. Traditionally, there are five
first-line drugs, including INH, RIF, Pyrazinamide (PZA), EMB
and SM. Second-line drugs contain aminoglycosides, Kana-
mycin and Amikacin, the polypeptide Capreomycin, Phage
antibiotic synergy (PAS), cycloserine, thioamides, ethiona-
mide and prothionamide and several fluoroquinolones, such
as ofloxacin, moxifloxacin, levofloxacin and gatifloxacin; SM
has been reported as a second-line drug, though [1].
For drug resistance, the following terms were used as de-
fined by the WHO [15]:
• MDR: multi-drug resistant tuberculosis (MDR-TB) is resis-
tance to at least two of the best anti-TB drugs, INH and RIF.
• XDR: extensively drug resistant tuberculosis (XDR-TB) is
resistance to: INH and RIF plus resistance to the best sec-
ond-line medications: fluoroquinolones and at least one
of three injectable drugs (i.e., Amikacin, Kanamycin, or
Capreomycin).
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In this study, the following terms were also used:
• Mono: it is resistant to at least INH or RIF.
• FLR: first-line drug-resistant isolates are MDR (resistant to
INH and RIF), plus resistant to PZA, EMB, and SM.
• TMDR (Total MDR): in this study, as a clinical aspect based
on clinical differences, MDR patients were divided into
MDR and FLR. In some parts, the general term MDR was
used as defined by the WHO. For this purpose, these two
terms were combined and were named TMDR.
• Male/female ratio: male/female ratios were calculated for
all groups, in terms of the total number of men to the total
number of women in each group.
• Working age: all patients were divided into two groups:
working age patients (18–60 for men and 18–55 for women)
and non-working age patients (including men or women
under 18, men over 60 and women over 55); p-values were
used for evaluation of the significance of differences that
have been found among the groups.
• Data analysis: the collected data were analyzed using Stat-
istica and Microsoft Office Excel software programs. As a
criterion, reliability differences indicators used the profile
p < 0.05.Results
During the research period, 934 pulmonary TB patients were
studied, of which 274 (29.33 ± 1.5%) (p < 0.001) men in the
age group 25–65 years outnumbered women between 2.7
and 9.0 times more (Table 1); 660 (70.66 ± 1.5%) of the TB cases
were men.
In the age group <15–24, as well as in the age group over
65 years, the proportion of men and women were similar. In
the remaining age groups, the proportion of men with TB
was significantly higher than women. The total ratio of male
TB patients among the female patients of all groups surveyed
in 2007 was 2.4, which agrees with theWHO European Region.
In the age group 45–54 the male to female ratio was the high-
est among patients with TMDR-TB.
Frequency of MTB isolates with different levels of resistance,
depending on age and sex
Drug sensitivity of MTB of all 934 surveyed patients with TB in
2007 was studied by culture in the dilution of drugs in the
growth medium.
From a clinical aspect, patients were divided into five
groups based on levels of resistance of MTB to the primaryTable 1 – A statistical characterization of the studied population
Sex Number of men and women in age
<15 (n = 28) 15–24 (n = 98) 25–44 (n = 400) 45–54
Women 14 50.0 ± 5.3 47 47.9 ± 5.0 108 27.0 ± 2.2 34 16
Men 14 50.0 ± 5.3 51 52.1 ± 5.0 292 73.0 ± 2.2 169 8
P >0.05 >0.05 <0.001 <0.00anti-tuberculosis drugs. This idea was based on clinical
differences over the course of the disease and resistance to
anti-tuberculosis drugs. For example, to treat MDR-TB cases
resistant to INH and RIF (but not to EMB, PZA and SM) and
first-line-resistant TB (FLR-TB), cases were considered resis-
tant to all first-line drugs.
Mono-resistance TB cases are treated separately from the
drug-sensitive and MDR cases. Among patients with drug-
resistant TB in different age groups, significant differences
among men and women were noted. There were no differ-
ences by age group, when comparing male and female
populations with XDR-TB (p > 0.05), MDR-TB (p > 0.05) and
drug-sensitive TB (p > 0.05) (Table 2).
Drug susceptible group
This group is sensitive to INH, RIF and other drugs and is
26.5 ± 1.4% of all analyzed isolates; 32.26 ± 2.96% of themwere
isolated from female patients, and 67.74 ± 2.96% males
(p < 0.05). This group includes the largest number of patients
less than 15 years (16 people). In contrast to all other groups,
among TB patients younger than 15 years, the number of girls
(12.5 ± 3.69%) outnumbered boys (3.57 ± 1.43%) (p < 0.05). A
similar trendwas found inpatientsolder than65 years:women
were 25 ± 4.84%, while men were 8.3 ± 2.1% (p < 0.05) (Table 2).
Mono-resistant group (Mono)
Patients suffering resistance to one of the major anti-tubercu-
losis drugs (INH or RIF) was 7.7 ± 0.87% of those surveyed,
69.4 ± 5.4% of them were men (p < 0.05). In this group, there
were no girls under the age of 15 years (Table 2).
First-line resistant group (FLR-TB)
This group, which included 31.0 ± 1.51% of all surveyed con-
sisted of patients infected with MDR-isolates (resistant to
INH and RIF), which were also resistant to PZA, EMB and
SM. The group with the FLR-TB treated 51.8% of patients with
MDR-TB because they do not respond to treatment with INH,
RIF and first-line drugs. The ratio of men and women in this
group was 3.07; the difference in sex composition was ob-
served in the range of 15–24 years (women 22.8 ± 4.6%, men
5.8 ± 1.6% (p < 0.05) (Table 2).
Multi-drug resistant group
MDR-isolates were resistant to both of the best anti-tubercu-
losis drugs: INH and RIF. Patients with MDR-TB accounted for
28.9 ± 1.5% of all patients. If, in accordance with the WHO
requirements, patients with FLR-TB were added to this group,of TB patients based on sex differentiation.
groups (number and %) Total
(n = 203) 55–65 (n = 125) >65 (n = 80)
.7 ± 2.6 31 10.0 ± 2.7 40 50.0 ± 5.6 274 (29.3 ± 1.5)
3.3 ± 2.6 94 90.0 ± 2.7 40 50.0 ± 5.6 660 (70.66 ± 1.7)
1 <0.001 <0.05 934 (100%)
Table 2 – Frequency of MTB isolates from patients with different levels of drug resistance depending on age and sex.
Drug resistance group Gender Age ranges (year), as number(%) Total as, number%
<15 15–24 25–44 45–54 55–65 >65
Susceptible Women 10(12.5 ± 3.69) 6(7.5 ± 2.9) 27(33.7 ± 5.2) 9(11.25 ± 3.5) 8(10.0 ± 3.35) 20(25.0 ± 4.84) 80(32.26 ± 2.96)
Men 6(3.57 ± 1.43) 15(8.9 ± 2.2) 55(32.7 ± 3.6) 44(26.2 ± 3.4) 34(20.2 ± 3.1) 14(8.3 ± 2.1) 168(67.74 ± 2.96)
Total 16(6.45 ± 1.56) 21(8.4 ± 1.8) 82(33.0 ± 3.0) 53(21.3 ± 2.6) 42(16.9 ± 2.4) 34(13.7 ± 2.2) 248(26.5 ± 1.4)
Mono resistant (Mono) Women – 3(13.6 ± 7.3) 10(45.45 ± 10.6) 4(18.18 ± 8.2) 2(9.1 ± 6.1) 3(13.6 ± 7.3) 22(30.5 ± 5.4)
Men 2(4.0 ± 2.7) 5(10 ± 4.24) 23(46.0 ± 7.0) 12(24 ± 6.0) 4(8 ± 3.8) 4(8 ± 3.8) 50(69.4 ± 5.4)
Total 2(27 ± 1.90) 8(11.11 ± 3.7) 33(45.8 ± 5.8) 16(22.2 ± 4.9) 6(8.33 ± 3.2) 7(9.7 ± 3.4) 72(7.7 ± 0.87)
T MDR
First-line resistant
(FLR)
3(3.6 ± 2.0) 19(22.8 ± 4.6) 29(34.9 ± 5.2) 12(14.4 ± 3.8) 12(14.4 ± 3.8) 8(9.6 ± 3.2) 83(28.6 ± 2.6) 83(8.88%)
2(0.96 ± 0.6) 12(5.8 ± 1.6) 101(48.7 ± 3.4) 53(25.6 ± 3.0) 29(10.4 ± 2.4) 10(4.8 ± 1.5) 207(71.3 ± 2.65) 207(22.16%)
5(1.7 ± 0.75) 31(10.7 ± 1.8) 130(44.8 ± 2.9) 65(22.4 ± 2.4) 41(14.1 ± 2.0) 18(16.2 ± 2.3) 290(31.0 ± 1.51) 290(31.05%)
Multi-drug resistant
(MDR)
1(1.35 ± 1.34) 17(22.9 ± 4.9) 34(45.9 ± 5.8) 7(9.4 ± 3.4) 8(10.8 ± 3.6) 7(9.4 ± 3.4) 74(27.4 ± 2.7) 74(7.93%)
4(2.0 ± 1.0) 14(7.1 ± 1.8) 99(50.5 ± 3.5) 50(25.5 ± 3.1) 20(10.2 ± 2.16) 9(4.6 ± 1.5) 196(72.6 ± 2.7) 196(20.98%)
5(1.85 ± 0.82) 31(11.5 ± 1.2) 133(49.2 ± 3.0) 57(21.1 ± 2.5) 28(10.3 ± 5.76) 16(5.9 ± 1.43) 270(28.9 ± 1.5) 270(28.9%)
Extensively drug
resistant (XDR)
Women – 2(13.3 ± 8.7) 8(53.3 ± 12.8) 2(13.3 ± 8.7) 1(6.6 ± 0.4) 2(13.3 ± 8.7) 15(27.78 ± 0.6)
Men – 5(12.8 ± 5.3) 14(35.9 ± 7.6) 10(25.6 ± 7.0) 7(17.9 ± 6.1) 3(7.7 ± 4.2) 39(72.22 ± 0.6)
Total – 7(12.9 ± 4.5) 22(40.7 ± 6.7) 12(22.2 ± 5.6) 8(14.8 ± 4.8) 5(9.2 ± 3.9) 54(5.7 ± 2.4)
Sum 28 (2.99 ± 0.55) 98 (10.49 ± 1.0) 400 (42.8 ± 1.6) 203 (21.7 ± 1.3) 125 (13.4 ± 1.1) 80 (8.5 ± 0.9) 934 (100)
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Table 3 – Treatment status of patients when admitted to hospital, based on resistance groups.
Status Resistance groups
Susceptible Mono TMDR XDR* Total
MDR* FLR
Secondary tuberculosis 184 (48.1 ± 2.55) 33 (8.6 ± 1.43) 63 (16.5 ± 1.89) 91 (23.8 ± 2.17) 11 (2.87 ± 0.85) 382 (100%)
Primary tuberculosis 36 (8.7 ± 1.38) 33 (7.9 ± 1.32) 202 (48.8 ± 2.45) 103 (24.8 ± 2.12) 40 (9.66 ± 1.45) 414 (100%)
Total 220 (27.6 ± 1.58) 66 (8.3 ± 0.97%) 265 (33.3 ± 1.6%) 194 (24.3 ± 1.5%) 51 (6.4 ± 0.86%) 796 (100%)
* p < 0.05.
T
d
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will be 59.9 ± 1.6% of all patients enrolled in the study. In the
age group 15–24 years, the proportion of women with MDR-TB
was 22.9 ± 4.9%, while the proportion of men was 7.1 ± 1.8%
(p < 0,05) (Table 2).
Extensively drug resistant group
XDR-TB is resistant to INH and RIF, as well as to any of the sec-
ond choice of drugs: fluoroquinolones and at least one of
three injectable drugs (i.e., Amikacin, Kanamycin and Capre-
omycin). During 2007, the lab was sent isolates from 54 pa-
tients (5.7 ± 2.4% of all surveyed) diagnosed with XDR-TB.
Men accounted for 39 (4.1 ± 0.6%), and the women accounted
for 15 (1.6 ± 0.4%) of them (p < 0.05); children in this group
were not accounted for. The greatest number of patients
was found in the age group 25–44 years (40.7 ± 6.7%) (Table 2).
Treatment status
From another aspect, all groups were divided into two catego-
ries based on treatment or non-treatment status when re-
ferred to hospital (see Table 3).
Patients with secondary TB totaled 414 (52.02 ± 1.77%), and
patients with primary TB totaled-382 (47.98 ± 1.77%) (p > 0.05).
Patients with primary TB were significantly more distin-
guished because MTB is sensitive to anti-tuberculosis drugs
(48.1 ± 2.55%), while only 8.7 ± 1.38% of cases (p < 0.05) of pa-able 4 – Results of the comparison between the detection rate o
isabled working age.
Drug Resistance Age Sex
Susceptible Non- working Men
Wome
Working Men
Wome
Mono-resistant Non- working Men
Wome
Working Men
Wome
TMDR Non- working Men
Wome
Working Men
Wome
XDR Non- working Men
Wome
Working Men
Wometients with secondary TB were detected. The frequency of
drug-resistant MTB in patients with secondary TB was 378
(47.48 ± 1.77%), which was significantly higher than in the
group suffering from primary TB: 198 (24.8 ± 1.52%) (p < 0.05).
It should be emphasized that a similar result was related to
XDR patients (p < 0.05).
Characteristics of drug resistance in the working age group
The p-value was calculated for the evaluation of the signifi-
cance of differences among age groups. In this way, all MDR
patients were added to those with FLR. Subsequently, MDR
patients in these sections include all patients that are resis-
tant to all first-line drugs and ones that are resistant only to
INH and RIF (as in TMDR). In Table 4, some groups with signif-
icant differences are shown.
Out of a total of 756 patients of working age, 570
(75.4 ± 1.56%) of them were men (working age 18–60 years)
and 186 (24.6 ± 1.56%) were women (working age 18–55 years).
Study of some groups that show significant differences
Patients with MDR-TB and FLR were merged into one group
renamed TMDR that included patients infected with strains
resistant to all first-line drugs, and strains resistant only to
INH and RIF. Men patients in mono-resistant, TMDR and
XDR groups have a similar frequency (p > 0.05). In susceptiblef MTB with different levels of resistance among patients and
Patients, Number and% P value
33 (46.4 ± 0.35%) p < 0.05
n 38 (53.5 ± 0.35%)
127 (75.59 ± 3.3%) p < 0.05
n 41 (24.4 ± 3.3%)
6 (42,85 ± 13,2%) p > 0.05
n 8 (57.15 ± 13,2%)
44 (70,96 ± 5.76%) p < 0.05
n 18 (29 ± 5.76%)
39 (50 ± 5.66%) p > 0.05
n 39(50 ± 5.66%)
364(75.5 ± 1.95%) p < 0.05
n 118(24.48 ± 1.95%)
4 (57.1 ± 18.7%) p > 0.05
n 3 (42.8 ± 18.7%)
35 (76.0 ± 6.28%) p < 0.05
n 11 (23.9 ± 6.28%)
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were more prevalent in men (p < 0.05).
It should be noted that 560 (59.95 ± 1.6%) patients had
MDR-TB and FLR-(TMDR), which is an isolated pathogen resis-
tant to at least INH and RIF (51.78 ± 2.1% of all patients with
TB TMDR-FLR-treated group). This means that approximately
half of the TB patients at admission were not responding to
therapy with INH, RIF or other first-line drugs, which greatly
increases the importance of developing rapid and efficient
methods for detection of resistant forms of the parasite.Discussion
In this study, from a clinical aspect, the patients were divided
into five groups based on resistance to principal anti-myco-
bacterium drugs. This idea was based on the clinical differ-
ences between, for example, an MDR case resistant to INH
and RIF (but not to EMB, PZA, or SM) and an FLR case resistant
to all first-line drugs. As recommended by the WHO, both of
the FLR and MDR groupswere treated as MDR. For this reason,
these items were added. In this respect, mono-resistant cases
differ from susceptible and MDR cases.
Out of 934 pulmonary TB patients, 660 (70.7%) were men.
The gender differences were mainly seen in the age group
25–65; the largest differences were in the 25–44 age group,
and the lowest differences were in the <15 and >65 age
groups. The male/female ratio of above unity (>1) was the
same in all groups except in the susceptible group (0.6 and
0.7 for <15 and >65, respectively).
The proportions of tuberculosis in ages <15 and >65 were
3% and 8.56%, respectively. The male/female ratio in these
groups was equal. On the other hand, it was found that fe-
male patients in the susceptible group under age 15 and above
age 65 were more than men in number. This situation was
also seen in the 15–24 MDR age group, in contrast with all
other groups. Interestingly, there was not a single patient
<15 in the mono-resistant group (Mono).
Approximately 60% of all patients were MDR and FLR, at
least to INH and RIF; 51.8% of all MDR patients were in the
FLR group. It means that around half of the patients did not
respond to INH and RIF or to the remaining choices of the
first-line drugs, so more expensive and less effective drugs
must be used.
After childhood, it was noted that the incidence of TB was
consistently higher in males until after working age; 70% of
cases occurred in males. The greatest difference in rates be-
tween the genders was in the 24–44 age groups. This observa-
tion provides compelling evidence of real sex differences
rather than a bias in diagnosis and reporting, since this is a
group where women are known to have greater health-seek-
ing behavior.Working age
In this study some paired groups were compared in working
and non-working ages based on drug-resistant status. A total
of 756 working age (18–60) patients were referred to this labo-
ratory, including 570 males and 186 females.There were no significant differences among susceptible
women of working age (45 patients) and those with MDR
(126 patients) (p = 0.07). This result was the same as the
non-working age groups. That means women of working
and non-working age in Belarus in 2007 were possibly equally
at risk for MDR or a susceptible form of TB. For men, these re-
sults were the same. For example, there were no significant
differences among men of working age with regard to suscep-
tible forms of XDR or MonoTB (p = 0.32 and 0.07, respectively).
Furthermore, no significant differences were detected among
men in working age in MDR and XDR (p = 0.7), MDR and Mono
(p = 0.32), etc.
A significant difference between susceptible men of work-
ing and non-working ages was found (p = 0.00001) (see Table
4). This result was also found for the other drug-resistant
groups, like XDR and MDR (p = 0001 for both). There were sig-
nificant differences among MDR men and women of working
age (p = 0.0001) (see Table 4). This situation is the same as in
the susceptible group (p = 0.016), but among XDR and Mono
in the same groups (men and women of working age) there
were no significant differences (p = 0.28 and 0.53, respec-
tively). It was concluded that in Belarus in 2007, men rather
than women were at higher risk for MDR or susceptible TB
at working age (but not for XDR and mono forms of TB). On
the other hand, there were no significant differences among
men and women of non-working age with susceptible Mono
resistance and XDR forms of TB (p = 0.21, 0.36 and 0.41,
respectively).
Susceptible men of working age (127 patients) did not have
significant differences with XDR patients (35 patients)
(p = 0.32) and with Mono resistant patients (44 patients,
p = 0.1). In other words, men of working age were possibly
equally contracting any form of TB. Interestingly, a significant
difference (p = 0.016) between groups of susceptible working
men and susceptible working women was found. Based on
the ages of patients, in the susceptible group, there was a
higher risk of TB for men than for women.
This research searched for the existence of a correlation
between ‘‘work and TB’’. There were significant differences
among susceptible non-working and working men and MDR
and XDR non-working and working men (p = 0.00001, 0.0001
and 0.0001, respectively), but no correlation was found be-
tween women in such groups (p = 0.07, 0.22 and 0.1, respec-
tively). It was concluded that tuberculosis in Belarus in 2007
was a disease that correlates to working status in men (but
not for women). However, a significant difference was found
between susceptible and MDR men based on age (p = 0.01).
This means men in Belarus in 2007 were contracting MDR-
TB rather than the susceptible form (based on ages of pa-
tients) (p = 0.0001). It was not seen between Mono in men
(p = 0.82).
Male/female
TB patients are more commonly males than females in most
countries. This difference is probably partly owing to the fact
that women have less access to diagnostic facilities in some
settings, but the broader pattern also reflects real epidemio-
logical differences between men and women, both in expo-
sure to infection and susceptibility to disease [10].
I n t e r n a t i o n a l J o u r n a l o f M y c o b a c t e r i o l o g y 1 ( 2 0 1 2 ) 7 5 –8 1 81The results of this study show that the male/female ratio
was >1 in almost all 15–65 age groups but differed in <15
and >65 groups. Overall, in 2007, the male/female ratio was
2.4 (see Table 4) for the referred patients. The male/female ra-
tio for susceptible strains increased with increasing age, and
its maximum was at 25–65, but it was unlike the ratio for
XDR strains. The male/female ratio for XDR-TB was the high-
est for all age groups over 45.
Variety of social and economic roles and activities may
cause differential exposure to bacilli responsible for TB. The
rate of progression from infection to disease in TB-infected
people is influenced by general health/nutritional condition.
A number of studies suggest that responses to illness differ
in women and men, and also barriers to early detection and
treatment of TB vary (and are probably greater) more for wo-
men than for men. Gender differences also exist in rates of
compliance with treatment. As children’s health and welfare
are in direct relation with that of their mothers, families and
households can be influenced by women suffering from TB.
Socio-economic and cultural factors may be important in
two ways. First, they may play a role in determining
overall gender differences in rates of infection and progres-
sion to disease, and secondly, they may lead to gender
differentials in barriers to detection and successful treatment
of TB [16].
Conclusion
TB is a matter of concern for all countries in Europe. The east-
ern part of the European Region and the former Soviet Union
with higher notification rates of TB remains a priority for TB
surveillance in the WHO European Region. The results illus-
trate the significance of national efforts to improve treatment
and control of drug-resistant TB in Belarus by implementing
evidence-based measures to regulate the monitoring of TB
treatment and contact tracing. As Belarus is a high-burden
MDR-TB country and treatment of drug-resistant TB is long
and complicated, these findings suggest that the effective
management of drug-resistant TB at the national level
will positively influence national productivity. Further
investigation is recommended via a representative survey of
drug-resistant TB among all culture-positive TB patients
notified in the country, with follow-up of their treatment
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